VTYX VENTYX BIOSCIENCES INC Investments/Divestments 8-K Filing 2023 - Product Launch Ventyx Biosciences, Inc. announced topline Phase 2 data for its novel oral S1P1 receptor modulator, VTX002, through a press release and a webcast.Get access to all SEC 8-K filings of the VENTYX BIOSCIENCES INC